When Statins Aren't Enough: New Trial Drug Points To Better Management Of Coronary Heart Disease

Despite widespread use of cholesterol-lowering drugs, a significant number of cardiac patients continue to suffer heart attacks and stroke. Researchers theorize that high levels of an enzyme found in coronary plaques may be to blame, by making plaques more likely to rupture and block blood flow. The drug darapladib may offer a way to fight that risk, according to new research.

Read the whole article on Science Daily

More from Science Daily